Tytuł pozycji:
Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study
-
Tytuł:
-
Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study
-
Autorzy:
-
Auliac, J. B.
Fournier, C.
Audigier Valette, C.
Perol, M.
Bizieux, A.
Vinas, F.
Decroisette Phan van Ho, C.
Bota Ouchlif, S.
Corre, R.
Le Garff, G.
Fournel, P.
Baize, N.
Lamy, R.
Vergnenegre, A.
Arpin, D.
Marin, B.
Chouaid, C.
Gervais, R.
-
Źródło:
-
Targeted Oncology. April 2016 11(2):167-174
-